Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Nasdaq · Healthcare · Biotechnology
$5.85−4.57%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $113M
- 52-week range
- $5.83 – $20.56
- 52-week change
- −58.04%
- EPS (trailing)
- −$6.11
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 16, 2026
Fiscal year to Dec 2025
- Net income
- −$78.5M
- Diluted EPS
- −$5.90
- Free cash flow
- −$64.5M
From the company’s annual report on SEC EDGAR.
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Headquarters: Norwood, United States · 36 employees · corbuspharma.com